SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-23-008667 to Vireo Growth Inc. (VREOF)

Vireo Growth Inc.
Date: Aug. 9, 2023 · CIK: 0001771706 · Accession: 0000000000-23-008667

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-273728

Date
August 9, 2023
Author
J. Michael Schroeder, Esq.
Form
UPLOAD
Company
Vireo Growth Inc.

Letter

United States securities and exchange commission logo August 9, 2023 J. Michael Schroeder, Esq. General Counsel and Corporate Secretary Goodness Growth Holdings, Inc. 207 South 9th Street Minneapolis, Minnesota 55402 Re:Goodness Growth Holdings, Inc. Registration Statement on Form S-1 Filed August 4, 2023 File No. 333-273728 Dear J. Michael Schroeder: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Tim Buchmiller at (202) 551-3635 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Thomas M. Rose, Esq.

Show Raw Text
United States securities and exchange commission logo
August 9, 2023
J. Michael Schroeder, Esq.
General Counsel and Corporate Secretary
Goodness Growth Holdings, Inc.
207 South 9th Street
Minneapolis, Minnesota 55402
Re:Goodness Growth Holdings, Inc.
Registration Statement on Form S-1
Filed August 4, 2023
File No. 333-273728
Dear J. Michael Schroeder:
            This is to advise you that we have not reviewed and will not review your registration
statement.
            Please refer to Rules 460 and 461 regarding requests for acceleration.  We remind you
that the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
            Please contact Tim Buchmiller at (202) 551-3635 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences
cc:       Thomas M. Rose, Esq.